Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, 226014, India.
Centre for Rheumatology, Calicut, Kerala, India.
Rheumatol Int. 2017 Nov;37(11):1773-1778. doi: 10.1007/s00296-017-3830-2. Epub 2017 Oct 5.
Scientific publishing, including in the field of Rheumatology, is evolving rapidly. Predatory journals are one of the major threats to contemporary publishing, especially to eager and naïve authors. In this narrative review, we discuss mechanisms that authors can employ to white list genuine scientific journals and blacklist "predatory" ones. Inclusion of a journal in reputed indices such as Medline (but not just Pubmed), Web of Science, Scopus or Embase raises the likelihood that the journal is genuine, more so if it is included in the current Journal Citation Reports. Other commercially available whitelists also exist, so also whitelists published by regulatory authorities in some countries. A commercially available blacklist has emerged since the very useful Beall's blacklist became defunct. In the absence of access to a whitelist or blacklist, certain characteristics such as repeated email solicitations for articles with an extremely narrow deadline from unknown sources, lack of inclusion in reputed indices, journals not published or endorsed by national or international society and scarcity of currently published articles should render authors suspicious of the genuine nature of a journal. National societies should work together to generate subject-specific (including Rheumatology specific) whitelists that can be available free of cost to authors from all over the world.
科学出版,包括风湿病学领域,正在迅速发展。掠夺性期刊是当代出版的主要威胁之一,尤其是对渴望和天真的作者。在这篇叙述性评论中,我们讨论了作者可以用来将真正的科学期刊列入白名单和将“掠夺性”期刊列入黑名单的机制。期刊被列入 Medline(但不仅限于 Pubmed)、Web of Science、Scopus 或 Embase 等知名索引中,增加了该期刊是真实的可能性,如果它被列入当前的期刊引文报告中,则更是如此。其他商业可用的白名单也存在,一些国家的监管机构也发布了白名单。自从非常有用的 Beall 黑名单失效以来,一个商业可用的黑名单已经出现。在无法访问白名单或黑名单的情况下,某些特征,如来自未知来源的极窄截止日期的文章的重复电子邮件征集,未被列入知名索引,期刊未被国家或国际学会出版或认可,以及目前发表的文章稀缺,这些都应该使作者对期刊的真实性产生怀疑。各国学会应共同努力,生成特定主题(包括风湿病学特定主题)的白名单,供来自世界各地的作者免费使用。